Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
Business segments
Q1 2026 · $39.8MThe company’s own SEC segment disclosure.
- US$38.7M97%
- Non Us$1.1M3%
GRAIL, Inc. (GRAL) reported revenue of $45M in Q2 2026 (quarter ended June 30, 2026), up 26% from the same quarter a year earlier. That came with net loss of $110M. For the full year FY2025, revenue was $147M (+17% year on year) and net income −$408M. Its largest region in 2026-Q1 was US at $39M, 97% of the disclosed total, just ahead of Non Us at 2.8%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #27 of 29 by Smart Score